PubRank

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Clinical Trial ID NCT00938652

PubWeight™ 26.96‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00938652

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010 3.98
2 Targeted therapies for breast cancer. J Clin Invest 2011 2.22
3 Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011 2.01
4 Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011 1.52
5 Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011 1.31
6 Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014 1.27
7 Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013 1.26
8 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016 1.18
9 Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010 1.17
10 Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012 1.17
11 γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta 2012 1.07
12 Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010 1.07
13 Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin 2010 1.06
14 Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012 1.01
15 Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013 1.01
16 Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010 0.98
17 PARP and cancer--if it's broke, don't fix it. N Engl J Med 2011 0.96
18 Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011 0.90
19 Combining emerging agents in advanced breast cancer. Oncologist 2011 0.83
20 Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther 2016 0.75
21 AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. Breast Care (Basel) 2011 0.75
Next 100